Gilead Sciences | GILD - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -5.94B 721M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Biogen USD 18.85B 196.3M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Coherus Biosciences USD 60.84M 17.78M 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Gilead Sciences USD 11.74B 11.77B 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Incyte USD 6.34B 721.58M 2026-06
J&J USD 84.97B 3.78B 2026-06
Merck USD 41.93B 3.94B 2026-06
Moderna USD 6.76B 647M 2026-06
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 41.95B 3.02B 2026-06
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD -165.36M 15.1M 2026-06
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 69.57B 3.24B 2026-06
Sarepta Therapeutics USD 1.53B 22.7M 2026-06
United Therapeutics USD 6.4B 499.2M 2026-06
Vertex Pharmaceuticals USD 20.25B 886M 2026-06